M. Diane Lougheed

M. Diane Lougheed

Auto-generated profile, based on publicly available information

M. Diane Lougheed

Asthma Research Unit, Kingston Health Sciences Centre, 76 Stuart Street, Kingston, ON, K7L 2V7, Canada, 1 6474608012

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Canadian Respiratory Journal
Verified
Journal Article
Open access
PDF file
MLM Diane Lougheed
M Diane Lougheed
LXLemi&# Xe8
Lemi&# Xe8
CRCatherine Re
Catherine Re
SDSharon D Dell
Sharon D Dell
FDFrancine M Ducharme
Francine M Ducharme
LBLouis-Philippe Boulet
Louis-Philippe Boulet
BACKGROUND/OBJECTIVE: To integrate new evidence into the Canadian Asthma Management Continuum diagram, encompassing both pediatric and adult asthma.METHODS: The Canadian Thoracic Society Asthma Committee members, comprised of experts in pediatric and adult respirology, allergy and immunology, emergency medicine, general pediatrics, family medicine, pharmacoepidemiology and evidence‐based medicine, updated the continuum diagram, based primarily on the 2008 Global Initiative for Asthma guidelines, and performed a focused review of literature pertaining to key aspects of asthma diagnosis and management in children six years of age and over, and adults.RESULTS: In patients six years of age and over, management of asthma begins with establishing an accurate diagnosis, typically by supplementing medical history with objective measures of lung function. All patients and caregivers should receive self‐management education, including a written action plan. Inhaled corticosteroids (ICS) remain the first‐line controller therapy for all ages. When asthma is not controlled with a low dose of ICS, the literature supports the addition of long‐acting beta2‐agonists in adults, while the preferred approach in children is to increase the dose of ICS. Leukotriene receptor antagonists are acceptable as second‐line monotherapy and as an alternative add‐on therapy in both age groups. Anti‐immunoglobulin E therapy may be of benefit in adults, and in children 12 years of age and over with difficult to control allergic asthma, despite high‐dose ICS and at least one other controller.CONCLUSIONS: The foundation of asthma management is establishing an accurate diagnosis based on objective measures (eg, spirometry) in individuals six years of age and over. Emphasis is placed on the similarities and differences between pediatric and adult asthma management approaches to achieve asthma control.

28 January 2019 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
PMPlinio Morita
Plinio Morita
MYMelanie S Yeung
Melanie S Yeung
MFMadonna Ferrone
Madonna Ferrone
ATAnn K Taite
Ann K Taite
CMCarole Madeley
Carole Madeley
CLChristopher Licskai
Christopher Licskai
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Uncontrolled asthma poses substantial negative personal and health system impacts. Web-based technologies, including smartphones, are novel means to enable evidence-based care and improve patient outcomes. Objective: To design, develop, and assess the utilization of an asthma collaborative self-management platform (breathe) using content based on international evidence-based clinical guidelines. Methods: Well-established user-centered design methods, combined with ISO-certified development processes were used to design and develop breathe. The data collection protocol collected user data for 12 months, with clinic visits at baseline, six, and 12 months. Utilization outcomes included user interactions with the platform, user impressions, self-reported medication use and asthma symptom profile, reported peak flow measurement, the delivery and response to e-mail reminders. Results: We designed and developed breathe as a web-based mHealth platform accessible on smartphones, tablets, or desktop. The system enabled collaborative self-management and self-monitoring of asthma patients through: (1) assessment of asthma control, (2) real-time access to a dynamic asthma action plan, (3) access to real-time environmental conditions, and (4) risk-reduction messaging. We enrolled 123 participants with a mean age of 45.2 years (Standard deviation (SD) ±15.8). A majority were female (72.5%), had a smartphone (66.7%), and had a mean Asthma Control Test score of 18.3 ± 4.9. Participants indicated a strong belief that the program had improved their ability to manage asthma and the tool scored 71.1 ± 18.9 on the System Usability Scale. The platform sent 7.96 reminder e-mails per patient per week (pppw), patients accessed breathe 3.08 times pppw, journaled symptoms 2.56 times pppw, reported medication usage 0.30 times pppw, and reported peak flow measurements 0.92 times pppw. breathe calculated patients’ action plan zone of control 2.72 times pppw, with patients being in the green (well-controlled) zone in 48% of the total calculations. Usage analysis showed that 60% of the participants used the app at week 4 and only 30% by week 45. Conclusions: breathe was designed and developed to enable patients to collaboratively self-manage their asthma. Strong usage is seen at the intervention’s initiation, followed by a reduction potentially due to the high proportion of well-controlled individuals with asthma, infrequent clinician surveillance, lack of a strong engagement technique, and patients achieving the right “digital dose” of the intervention. Usage patterns observed during this intervention provide important learnings for future mHealth developments regarding reminder design and sustained effects, ideal times for interaction with patient, surveillance effect, and engagement methods matched to patient health characteristics.

1 March 2009 in Chest
Verified
Journal Article
Closed access
MLM. Diane Lougheed
M. Diane Lougheed
NGNancy Garvey
Nancy Garvey
KCKenneth R. Chapman
Kenneth R. Chapman
LCLisa Cicutto
Lisa Cicutto
RDRobert Dales
Robert Dales
NPNigel A.M. Paterson
Nigel A.M. Paterson

22 May 2013 in Implementation Science
Verified
Journal Article
Open access
PDF file
MJMona Jabbour
Mona Jabbour
JCJanet Curran
Janet Curran
SSShannon D Scott
Shannon D Scott
AGAstrid Guttman
Astrid Guttman
TRThomas Rotter
Thomas Rotter
DJDavid W Johnson
David W Johnson
Background: The clinical pathway is a tool that operationalizes best evidence recommendations and clinical practice guidelines in an accessible format for ‘point of care’ management by multidisciplinary health teams in hospital settings. While high-quality, expert-developed clinical pathways have many potential benefits, their impact has been limited by variable implementation strategies and suboptimal research designs. Best strategies for implementing pathways into hospital settings remain unknown. This study will seek to develop and comprehensively evaluate best strategies for effective local implementation of externally developed expert clinical pathways. Design/methods: We will develop a theory-based and knowledge user-informed intervention strategy to implement two pediatric clinical pathways: asthma and gastroenteritis. Using a balanced incomplete block design, we will randomize 16 community emergency departments to receive the intervention for one clinical pathway and serve as control for the alternate clinical pathway, thus conducting two cluster randomized controlled trials to evaluate this implementation intervention. A minimization procedure will be used to randomize sites. Intervention sites will receive a tailored strategy to support full clinical pathway implementation. We will evaluate implementation strategy effectiveness through measurement of relevant process and clinical outcomes. The primary process outcome will be the presence of an appropriately completed clinical pathway on the chart for relevant patients. Primary clinical outcomes for each clinical pathway include the following: Asthma—the proportion of asthmatic patients treated appropriately with corticosteroids in the emergency department and at discharge; and Gastroenteritis—the proportion of relevant patients appropriately treated with oral rehydration therapy. Data sources include chart audits, administrative databases, environmental scans, and qualitative interviews. We will also conduct an overall process evaluation to assess the implementation strategy and an economic analysis to evaluate implementation costs and benefits. Discussion: This study will contribute to the body of evidence supporting effective strategies for clinical pathway implementation, and ultimately reducing the research to practice gaps by operationalizing best evidence care recommendations through effective use of clinical pathways. Trial registration: ClinicalTrials.gov:NCT01815710

1 June 2013 in Chest
Verified
Journal Article
Closed access
PDF file
STScott E. Turcotte
Scott E. Turcotte
ACAlex Chee
Alex Chee
RWRonald Walsh
Ronald Walsh
FGF. Curry Grant
F. Curry Grant
GLGary M. Liss
Gary M. Liss
MLM. Diane Lougheed
M. Diane Lougheed

3 December 2011 in Lung
Verified
Journal Article
Closed access
PDF file
MLM. Diane Lougheed
M. Diane Lougheed
STScott E. Turcotte
Scott E. Turcotte
TFThomas Fisher
Thomas Fisher